Ross Durland, Senior Vice President of Development, joins several new Cell Medica executive appointments who will seek to strengthen product development and international growth for the company in their new Houston-based office.
In an effort to strengthen product development and international growth, UK-based cellular therapeutics company Cell Medica has brought on several new executive appointments, including former Texas biotech professional Ross Durland, who will serve as Senior Vice President of Development for the company. The new executive appointments at Cell Medica, all of whom are to work out of the company’s Houston-based office, are aimed at further developing the company’s efforts to bring to market new, personalized cell therapies for the treatment of cancer and infections.
According to a Cell Medica press release, Mr. Durland:
” . . has over 20 years of experience in the development of highly innovative therapeutic products and technologies. He gained significant experience with cell-based therapeutics while at Valentis (formerly GeneMedicine; The Woodlands, TX) where he rose to Senior Director Preclinical Development and led multi-site, multidisciplinary product development teams advancing two new gene therapy products from animal proof-of-concept to human clinical testing. During his time at Valentis, Ross also participated in developing five additional clinical stage products, and led the company’s manufacturing and quality control functions in manufacturing products for preclinical and clinical testing.”
Given Cell Medica’s particular focus on product development, there is no doubt that Mr. Durland’s new role in the company will be a significant one, and that his experience in the Texas biotech sector will lend itself to allowing him to ” . . .focus on the Company’s pipeline strategy while also assisting in setting up the manufacturing operations in the U.S.” This, combined with the fact that Cell Medica has chosen Houston as its base of operations for these new initiatives, speaks to the ongoing growth and development of the biotech and life sciences sectors in Texas.